Genmab A/S to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, June 4, 2012 (GLOBE NEWSWIRE) --
Genmab A/S, an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Jan G. J. van de Winkel, President & CEO, will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Tuesday, June 5, 2012 – 3:45 p.m. to 4:00 p.m. ET
Rachel Curtis Gravesen
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Genmab A/S:
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
About NASDAQ OMX:
(C) Copyright 2012 GlobeNewswire, Inc. All rights reserved.